HOME >> MEDICINE >> NEWS
Iressa news backgrounder

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we would have liked
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
16-Oct-2003


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Iressa news backgrounder

(Date:5/30/2015)... Cyclist Barry Haarde will commence his ... 2015: Piles of Miles” near San Francisco, California ... and encourage individuals to support needy hemophilic children ... Life supports nearly 1,200 impoverished children and adults ... sponsorships, scholarships and micro-enterprise grants. Hemophilia is a ...
(Date:5/30/2015)... iconic American actor, and host of “In America” James ... Medical Malpractice. This segment of “In America” will cover ... field. , According to the Bureau of Justice Statistics, ... roughly only 20% of them made it to court, ... remaining 30% were tossed out. (Source: http://www.bjs.gov/index.cfm?ty=tp&tid=4511 ) ...
(Date:5/30/2015)... May 30, 2015 Venus Viva has ... scars, large pores, deep wrinkles, stretch marks, pigmentation irregularities, ... professional, such as Dr. F. Victor Rueckl of Lakes ... clinical trials in Las Vegas. This body image solution ... a system that delivers proven results through a skin ...
(Date:5/29/2015)... Based in St. Louis, Missouri La La ... for a couple of months now and are really helping ... reads “I’m not misbehaving, I have Autism, please be understanding” ... an autistic child in order to start a conversation and ... are they raising awareness through the autism awareness shirts which ...
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
Breaking Medicine News(10 mins):Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2Health News:MDLinx Launches Smartest Rheumatologist 2
(Date:5/29/2015)... , May 29, 2015  Anpac Bio-Medical Science Co., ... Yu and the Anpac research team are introducing ... Science (NPLS) organizers published as, "game changing" and "breakthrough" ... Society of Clinical Oncology (ASCO) Annual Meeting in ... 2, 2015. An accomplished inventor with ...
(Date:5/29/2015)... , May 29, 2015  Fair Rate Funding, ... a state-court jury in Delaware ... inserts, designed to treat pelvic organ prolapse (POP) and ... and that company executives hid the design flaws from ... - http://photos.prnewswire.com/prnh/20150529/219354LOGO Transvaginal mesh, ...
(Date:5/29/2015)... Actinobac Biomed, NovoPedics, Inc. and MentiNova, Inc., ... Foundation Venture Capital Group (FVCG), have been selected to ... of the Start-Up Stadium and Company Presentation forums offered ... Golubieski . The annual convention, the largest ... in Philadelphia in June. ...
Breaking Medicine Technology:Anpac Bio-Medical Introduces 'Game Changing' Cancer Screening Tech at American Society of Clinical Oncology Meeting - Chicago 5/29 - 6/2 2Anpac Bio-Medical Introduces 'Game Changing' Cancer Screening Tech at American Society of Clinical Oncology Meeting - Chicago 5/29 - 6/2 3TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict. 2TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict. 3Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3
Cached News: